Latest & greatest articles for risperidone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on risperidone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on risperidone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for risperidone

61. Cost-effectiveness model of long-acting risperidone in schizophrenia in the US

Cost-effectiveness model of long-acting risperidone in schizophrenia in the US Cost-effectiveness model of long-acting risperidone in schizophrenia in the US Cost-effectiveness model of long-acting risperidone in schizophrenia in the US Edwards N C, Rupnow M F T, Pashos C L, Botteman M F, Diamond R J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of a long-acting injection (LAI) formulation of risperidone (RIS) for the treatment of patients with schizophrenia. Patients could receive LAI RIS 25 mg, 37.5 mg or 50 mg, given at 14-day intervals. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised a hypothetical cohort of community

NHS Economic Evaluation Database.2005

62. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA

Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA Edwards N C, Locklear J C, Rupnow M F, Diamond R J Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared the following treatment options for patients with schizophrenia: long-acting risperidone, oral risperidone (average dose 3.8 mg/day), olanzapine (oral antipsychotic agent), long-acting injectable

NHS Economic Evaluation Database.2005

63. Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada

Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada Chue P S, Heeg B M, Buskens E, van Hout B A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared three treatment options for schizophrenia. The three treatment options differed in the starting treatment: haloperidol depot, a long-acting conventional antipsychotic agent, at a daily dose of 4.76 mg; long-acting risperidone, a long-acting atypical antipsychotic agent, at a daily dose of 2.3 mg; or oral risperidone, an oral

NHS Economic Evaluation Database.2005

64. Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs

Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated (...) (or atypical antipsychotics) for the treatment of schizophrenia. Each strategy comprised a first-line treatment, followed by alternative therapies if the patient did not respond to treatment. The three strategies were as follows. The risperidone strategy comprised initial treatment with long-acting risperidone, followed by a first alternative of olanzapine, a second alternative of clozapine, and a third alternative of depot haloperidol. The depot haloperidol strategy comprised initial treatment with depot

NHS Economic Evaluation Database.2005

65. Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol

Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol Kongsakon R, Leelahanaj T, Price N (...) , Birinyi-Strachan L, Davey P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Several medications for schizophrenia were examined. The four atypical antipsychotics studied were olanzapine (OLZ), risperidone (RISP), quetiapine (QUET

NHS Economic Evaluation Database.2005

66. Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis

Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis De Graeve D, Smet A, Mehnert, Caleo S, Miadi-Fargier H, Mosqueda G J, Lecompte D, Peuskens J Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared the following therapeutic strategies for patients with schizophrenia: first-line treatment with long-acting risperidone, 25 mg every 14 days (ambulatory care or hospital

NHS Economic Evaluation Database.2005

67. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany

Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany Laux G, Heeg B M S, van Hout B A, Mehnert A Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The three treatment strategies investigated were first-line treatment with haloperidol depot, long-acting risperidone and oral olanzapine for patients with schizophrenia. Type of intervention Treatment. Economic study type Cost-effectiveness analysis and cost-utility analysis. Study

NHS Economic Evaluation Database.2005

68. Economic outcomes associated with switching individuals with schizophrenia between risperidone and olanzapine: findings from a large US claims database

Economic outcomes associated with switching individuals with schizophrenia between risperidone and olanzapine: findings from a large US claims database Economic outcomes associated with switching individuals with schizophrenia between risperidone and olanzapine: findings from a large US claims database Economic outcomes associated with switching individuals with schizophrenia between risperidone and olanzapine: findings from a large US claims database Zhao Z Y, Namjoshi M, Barber B L, Loosbrock (...) D L, Tunis S L, Zhu B J, Breier A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of atypical antipsychotic agents, olanzapine (OLZ) and risperidone (RIS), for the treatment of patients with schizophrenia. Type

NHS Economic Evaluation Database.2004

70. Clinical trial response and dropout rates with olanzapine versus risperidone

Clinical trial response and dropout rates with olanzapine versus risperidone Clinical trial response and dropout rates with olanzapine versus risperidone Clinical trial response and dropout rates with olanzapine versus risperidone Santarlasci B, Messori A CRD summary This review assessed the use of olanzapine and risperidone for schizophrenia. The authors concluded that olanzapine appears to be associated with a lower drop-out rate than risperidone and it may improve long-term maintenance (...) of response, but further data on long-term maintenance are required. The authors' conclusions may not be reliable in view of the potential for various sources of bias. Authors' objectives To compare the drop-out and response rates between olanzapine and risperidone. Searching MEDLINE (from 1966 to May 2002), IDIS (from 1966 to May 2002) and the DRUGDEX databank (volume 112) were searched; the search terms were stated. Reference lists in identified studies were also reviewed. The search strategy

DARE.2003

71. Cost-effectiveness of amisulpride compared with risperidone in patients with schizophrenia

Cost-effectiveness of amisulpride compared with risperidone in patients with schizophrenia Cost-effectiveness of amisulpride compared with risperidone in patients with schizophrenia Cost-effectiveness of amisulpride compared with risperidone in patients with schizophrenia Nicholls C J, Hale A S, Freemantle N Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) for the AMIRIS study. There were 152 patients received amisulpride and 158 patients received risperidone. Study design The study was a randomised multi-centre clinical trial. The period of observation was 6 months of treatment, with the possibility of extension to 12 months. Analysis of effectiveness The basis of the analysis of effectiveness was intention to treat. The primary health outcome was assessed using the PANSS. The secondary health outcomes were assessed using the BPRS and the Clinical Global

NHS Economic Evaluation Database.2003

72. Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis

Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis Taylor D M, Wright T, Libretto S E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions (...) followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two atypical antipsychotics for the first-line treatment of schizophrenia or schizoaffective disorders are compared: risperidone and olanzapine. Mean (+/- SD) doses were 5.5 (+/- 2.4) mg/day for risperidone and 14.1 (+/- 4.7) mg/day for olanzapine. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised

NHS Economic Evaluation Database.2003

73. Risperidone orodispersible tablets (Risperdal Quicklet) - Acute and chronic schizophrenic psychoses

Risperidone orodispersible tablets (Risperdal Quicklet) - Acute and chronic schizophrenic psychoses Secretariat - Delta House 50 West Nile Street Glasgow G1 2NP Telephone 0141 225 6997 Fax 0141 248 3778 E-mail jmitchell@htbs.org.uk Chairman Professor David Lawson Scottish Medicines Consortium Risperidone orodispersible tablets (Risperdal Quicklet Ò ) (No. 41/03) Janssen-Cilag Ltd Summary of Recommendation 9 May 2003 The Scottish Medicines Consortium (SMC) has completed its assessment

Scottish Medicines Consortium2003

74. Depot risperidone for schizophrenia.

Depot risperidone for schizophrenia. BACKGROUND: Risperidone is the first new generation antipsychotic drug made available in a long acting injection. OBJECTIVES: To examine the clinical effects of depot risperidone for people with schizophrenia and schizophrenia-like psychoses. SEARCH STRATEGY: We searched the Cochrane Schizophrenia Group's Register (December 2002), references of all included studies, and contacted industry and authors of included studies. SELECTION CRITERIA (...) : Randomised clinical trials comparing depot risperidone with other treatments for people with schizophrenia and/or schizophrenia-like psychoses. DATA COLLECTION AND ANALYSIS: Two reviewers independently inspected citations and/or abstracts, ordered papers, re-inspected and quality assessed the results, and extracted data. For dichotomous data, we calculated the relative risk (RR), the 95% confidence interval (CI) and, where appropriate, the number needed to treat (NNT), on an intention-to-treat basis. For continuous data

Cochrane2003

75. Risperidone versus typical antipsychotic medication for schizophrenia.

Risperidone versus typical antipsychotic medication for schizophrenia. BACKGROUND: Risperidone is one of the 'new generation' antipsychotics. As well as its reputed tendency to cause fewer movement disorders than the older drugs such as chlorpromazine and haloperidol, it is claimed that risperidone may improve negative symptoms. OBJECTIVES: To evaluate the effects of risperidone for schizophrenia in comparison to 'conventional' neuroleptic drugs. SEARCH STRATEGY: The original electronic (...) citations. Pharmaceutical companies and authors of trials were also contacted. SELECTION CRITERIA: All randomised trials comparing risperidone to any 'conventional' neuroleptic treatment for people with schizophrenia or other similar serious mental illnesses. DATA COLLECTION AND ANALYSIS: Citations and, where possible, abstracts were independently inspected by reviewers, papers ordered, re-inspected and quality assessed. Data were also independently extracted. Where possible, sensitivity analyses

Cochrane2003

76. Risperdal (risperidone)

Risperdal (risperidone) Drug Approval Package: Risperdal (risperidone) NDA #021444 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Drug Review Package Risperdal (risperidone) Tablets Company: Johnson & Johnson Application No.: 021444 Approval Date: 4/2/2003 (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: July 15, 2003 Note: Documents in PDF format require the . - - Links on this page: Note: If you need help accessing

FDA - Drug Approval Package2003

77. Risperidone Consta complete Drug Approval Package (all reviews)

Risperidone Consta complete Drug Approval Package (all reviews) Oregon Health & Science University OHSU Digital Commons FDA Drug Approval Documents October 2003 Risperidone Consta complete Drug Approval Package (all reviews) United States. Food and Drug Administration. Follow this and additional works at: http://digitalcommons.ohsu.edu/fdadrug This Article is brought to you for free and open access by OHSU Digital Commons. It has been accepted for inclusion in FDA Drug Approval Documents (...) by an authorized administrator of OHSU Digital Commons. For more information, please contact champieu@ohsu.edu. Recommended Citation United States. Food and Drug Administration., "Risperidone Consta complete Drug Approval Package (all reviews)" (2003). FDA Drug Approval Documents. 16. http://digitalcommons.ohsu.edu/fdadrug/16PDF page 1 of 288 CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 21-346 STATISTICAL REVIEW(S) PDF page 2 of 288 DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE

FDA Drug Approval Documents (via OHSU)2003

78. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study.

Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. OBJECTIVE: To quantify the association between olanzapine and diabetes. DESIGN: Population based nested case-control study. SETTING: United Kingdom based General Practice Research Database comprising 3.5 million patients followed between 1987 and 2000. PARTICIPANTS: 19 637 patients who had been diagnosed as having and treated (...) for schizophrenia. 451 incident cases of diabetes were matched with 2696 controls. MAIN OUTCOME MEASURES: Diagnosis and treatment of diabetes. RESULTS: Patients taking olanzapine had a significantly increased risk of developing diabetes than non-users of antipsychotics (odds ratio 5.8, 95% confidence interval 2.0 to 16.7) and those taking conventional antipsychotics (4.2, 1.5 to 12.2). Patients taking risperidone had a non-significant increased risk of developing diabetes than non-users of antipsychotics (2.2

BMJ2002 Full Text: Link to full Text with Trip Pro

79. Costs and outcomes of risperidone treatment in schizophrenia in the Czech Republic

Costs and outcomes of risperidone treatment in schizophrenia in the Czech Republic Costs and outcomes of risperidone treatment in schizophrenia in the Czech Republic Costs and outcomes of risperidone treatment in schizophrenia in the Czech Republic Hosak L, Bahbouh R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed (...) critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of risperidone versus standard neuroleptics in the treatment of schizophrenia. Standard neuroleptics comprised a combination of chlorpromazine, chlorprothixene, haloperidol, levomepromazine, oxyprothepine, perfenazine and thioridazine. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients aged between 18 and 65 years

NHS Economic Evaluation Database.2002

80. A pharmacoeconomic evaluation of zuclopenthixol compared with haloperidol and risperidone in the treatment of schizophrenia

A pharmacoeconomic evaluation of zuclopenthixol compared with haloperidol and risperidone in the treatment of schizophrenia A pharmacoeconomic evaluation of zuclopenthixol compared with haloperidol and risperidone in the treatment of schizophrenia A pharmacoeconomic evaluation of zuclopenthixol compared with haloperidol and risperidone in the treatment of schizophrenia Hansen K, Francois C, Toumi M, Lancon C Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Three treatments for schizophrenia were examined: zuclopenthixol (ZUC), a neuroleptic belonging to the family of thioxanthenes, which are conventional agents; haloperidol (HAL), another conventional agent; and risperidone (RIS), a new combined two-serotonin and two

NHS Economic Evaluation Database.2002